Literature DB >> 12509471

Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.

M C McGuinness1, J-F Lu, H-P Zhang, G-X Dong, A K Heinzer, P A Watkins, J Powers, K D Smith.   

Abstract

Peroxisomal disorders have been associated with malfunction of peroxisomal metabolic pathways, but the pathogenesis of these disorders is largely unknown. X-linked adrenoleukodystrophy (X-ALD) is associated with elevated levels of very-long-chain fatty acids (VLCFA; C(>22:0)) that have been attributed to reduced peroxisomal VLCFA beta-oxidation activity. Previously, our laboratory and others have reported elevated VLCFA levels and reduced peroxisomal VLCFA beta-oxidation in human and mouse X-ALD fibroblasts. In this study, we found normal levels of peroxisomal VLCFA beta-oxidation in tissues from ALD mice with elevated VLCFA levels. Treatment of ALD mice with pharmacological agents resulted in decreased VLCFA levels without a change in VLCFA beta-oxidation activity. These data indicate that ALDP does not determine the rate of VLCFA beta-oxidation and that VLCFA levels are not determined by the rate of VLCFA beta-oxidation. The rate of peroxisomal VLCFA beta-oxidation in human and mouse fibroblasts in vitro is affected by the rate of mitochondrial long-chain fatty acid beta-oxidation. We hypothesize that ALDP facilitates the interaction between peroxisomes and mitochondria, resulting, when ALDP is deficient in X-ALD, in increased VLCFA accumulation despite normal peroxisomal VLCFA beta-oxidation in ALD mouse tissues. In support of this hypothesis, mitochondrial structural abnormalities were observed in adrenal cortical cells of ALD mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509471      PMCID: PMC151532          DOI: 10.1128/MCB.23.2.744-753.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  M Dean; Y Hamon; G Chimini
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

2.  Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.

Authors:  L Bezman; A B Moser; G V Raymond; P Rinaldo; P A Watkins; K D Smith; N E Kass; H W Moser
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

3.  The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression.

Authors:  J Berger; S Albet; M Bentejac; A Netik; A Holzinger; A A Roscher; M Bugaut; S Forss-Petter
Journal:  Eur J Biochem       Date:  1999-10

4.  Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome.

Authors:  S Goldfischer; C L Moore; A B Johnson; A J Spiro; M P Valsamis; H K Wisniewski; R H Ritch; W T Norton; I Rapin; L M Gartner
Journal:  Science       Date:  1973-10-05       Impact factor: 47.728

Review 5.  Peroxisomes (microbodies and related particles).

Authors:  C De Duve; P Baudhuin
Journal:  Physiol Rev       Date:  1966-04       Impact factor: 37.312

Review 6.  Composition, structure, and function of complex III of the respiratory chain.

Authors:  J S Rieske
Journal:  Biochim Biophys Acta       Date:  1976-09-27

7.  The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria.

Authors:  J M Powers; D P DeCiero; C Cox; E K Richfield; M Ito; A B Moser; H W Moser
Journal:  J Neuropathol Exp Neurol       Date:  2001-05       Impact factor: 3.685

8.  Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters.

Authors:  L X Liu; K Janvier; V Berteaux-Lecellier; N Cartier; R Benarous; P Aubourg
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

9.  Pharmacological induction of peroxisomes in peroxisome biogenesis disorders.

Authors:  H Wei; S Kemp; M C McGuinness; A B Moser; K D Smith
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

10.  Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse).

Authors:  E Baumgart; I Vanhorebeek; M Grabenbauer; M Borgers; P E Declercq; H D Fahimi; M Baes
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

View more
  35 in total

Review 1.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 2.  Organelle dynamics and dysfunction: A closer link between peroxisomes and mitochondria.

Authors:  F Camões; N A Bonekamp; H K Delille; M Schrader
Journal:  J Inherit Metab Dis       Date:  2008-12-12       Impact factor: 4.982

Review 3.  Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Authors:  Johannes Berger; Aurora Pujol; Patrick Aubourg; Sonja Forss-Petter
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 4.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

5.  SOD2 as a potential modifier of X-linked adrenoleukodystrophy clinical phenotypes.

Authors:  Rebecca Deering Brose; Dimitri Avramopoulos; Kirby D Smith
Journal:  J Neurol       Date:  2012-01-05       Impact factor: 4.849

6.  A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination.

Authors:  Lauren R Strachan; Tamara J Stevenson; Briana Freshner; Matthew D Keefe; D Miranda Bowles; Joshua L Bonkowsky
Journal:  Hum Mol Genet       Date:  2017-09-15       Impact factor: 6.150

Review 7.  The peroxisomal ABC transporter family.

Authors:  Ronald J A Wanders; Wouter F Visser; Carlo W T van Roermund; Stephan Kemp; Hans R Waterham
Journal:  Pflugers Arch       Date:  2006-10-13       Impact factor: 3.657

8.  Probing substrate-induced conformational alterations in adrenoleukodystrophy protein by proteolysis.

Authors:  Carla P Guimarães; Clara Sá-Miranda; Jorge E Azevedo
Journal:  J Hum Genet       Date:  2005-01-29       Impact factor: 3.172

9.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

Review 10.  Therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.